SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001562180-20-007176
Filing Date
2020-12-10
Accepted
2020-12-10 17:30:02
Documents
2
Period of Report
2020-12-08

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primarydocument.html 4  
1 PRIMARY DOCUMENT primarydocument.xml 4 8858
2 RUDNICKPOA srudnickpoa.txt EX-24 3412
  Complete submission text file 0001562180-20-007176.txt   13818
Mailing Address 7100 WEST CREDIT AVENUE, SUITE 101 C/O ARALEZ PHARMACEUTICALS MISSISSAUGA A6 L5N 0E4
Business Address
RUDNICK SETH (Reporting) CIK: 0001184420 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38096 | Film No.: 201381563

Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Issuer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations